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Human mesenchymal stem cells (hMSCs) isolated from various tissues represent the most highly utilized cell 
type for cell therapy and regenerative medicine applications.  Given that large numbers of high quality cells are 
required for many applications and that large surface area requirement for cell expansion is necessary, a search 
for a practical manufacturing platform for cell expansion has been ongoing over the last decade.  Feasibility 
studies have demonstrated the utility of using microcarrriers in dynamic cultures for expansion of hMSCs and 
the results have positioned this technology as the platform of choice for the cost-effective generation of cells.  
Microcarrier cultures performed in fully closed single-use systems provide a cGMP-compliant platform for cell 
expansion and are a logical extension of traditional manufacturing technologies.   However the use of high 
quality cell banks and bioprocess medium in these platforms significantly impacts overall performance.  In 
addition, development of methods to reproducibly harvest and concentrate cells expanded on microcarriers in 
closed systems is critical. 
 
We have developed a rapid and robust manufacturing platform that enables reproducible expansion and harvest 
of 28 billion hMSCs from a one passage fed-batch microcarrier culture in a single use reactor seed train in only 
8 days.  Our system reproducibly achieves hMSC media productivity of > 500M cells/L of media consumed. 
Data will be presented from experiments using sterile microcarriers (Pall SoloHill) in single use bioreactors (Pall 
Corp) with high volume hMSC seed stock and a fed-batch bioprocess medium (RoosterBio), including quality 
parameters related to identity flow markers, angiogenic cytokine secretion profile, multi-lineage differentiation, 
and inducible immunomodulatory functions.  This system has the potential to be rapidly implemented at multiple 
sites enabling product developers to quickly produce tens of billions of high quality hMSCs for Regenerative 
Medicine product development programs. 
 
 
 
 
 
 
 
